Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
European Child & Adolescent Psychiatry
|
August 29, 2025
Correction: Effectiveness of a cognitive-behavioral sleep hygiene intervention for adolescents with ADHD: a randomized controlled trial
Lena Keuppens, Finja Marten, Dieter Baeyens, et al.
European Child & Adolescent Psychiatry
|
May 27, 2025
Effectiveness of a cognitive-behavioral sleep hygiene intervention for adolescents with ADHD: a randomized controlled trial
Lena Keuppens, Finja Marten, Dieter Baeyens, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 26, 2008
Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers
Myaing M Nyunt, Stephen Becker, Ron T MacFarland, et al.
The Journal of Infectious Diseases
|
March 16, 2011
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials
Peter B Gilbert, James O Berger, Donald Stablein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2009
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1
Graeme Moyle, Edwin DeJesus, Marta Boffito, et al.
Plos Pathogens
|
August 7, 2023
Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2
Gary Ewart, Michael Bobardt, Bo Hjorth Bentzen, et al.
The Journal of Antimicrobial Chemotherapy
|
March 14, 2007
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen
D William Cameron, Stephen Becker, Martin S King, et al.
Disease Markers
|
July 20, 2004
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers
Christine Laronga, Stephen Becker, Patrice Watson, et al.
The Journal of Infectious Diseases
|
October 10, 2020
Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation
Carolyn A Luscombe, Anchalee Avihingsanon, Khuanchai Supparatpinyo, et al.
AIDS Research and Human Retroviruses
|
May 18, 2019
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210
Victoria A Johnson, Yoninah S Cramer, Susan L Rosenkranz, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
European Child & Adolescent Psychiatry
|
August 29, 2025
Correction: Effectiveness of a cognitive-behavioral sleep hygiene intervention for adolescents with ADHD: a randomized controlled trial
Lena Keuppens, Finja Marten, Dieter Baeyens, et al.
European Child & Adolescent Psychiatry
|
May 27, 2025
Effectiveness of a cognitive-behavioral sleep hygiene intervention for adolescents with ADHD: a randomized controlled trial
Lena Keuppens, Finja Marten, Dieter Baeyens, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 26, 2008
Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers
Myaing M Nyunt, Stephen Becker, Ron T MacFarland, et al.
The Journal of Infectious Diseases
|
March 16, 2011
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials
Peter B Gilbert, James O Berger, Donald Stablein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 6, 2009
Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1
Graeme Moyle, Edwin DeJesus, Marta Boffito, et al.
Plos Pathogens
|
August 7, 2023
Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2
Gary Ewart, Michael Bobardt, Bo Hjorth Bentzen, et al.
The Journal of Antimicrobial Chemotherapy
|
March 14, 2007
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen
D William Cameron, Stephen Becker, Martin S King, et al.
Disease Markers
|
July 20, 2004
SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers
Christine Laronga, Stephen Becker, Patrice Watson, et al.
The Journal of Infectious Diseases
|
October 10, 2020
Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation
Carolyn A Luscombe, Anchalee Avihingsanon, Khuanchai Supparatpinyo, et al.
AIDS Research and Human Retroviruses
|
May 18, 2019
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210
Victoria A Johnson, Yoninah S Cramer, Susan L Rosenkranz, et al.
Page
of 5